Jazz Pharmaceuticals plc
JAZZ · NASDAQ-GS
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B |
| Research & Development | — | — | — | — | — | — | $299.73M | $226.62M |
| Selling, General & Administrative | $1.81B | $1.39B | $1.34B | $1.42B | $1.45B | $854.23M | $736.94M | $683.53M |
| Operating Expenses | $4.70B | $3.35B | $3.26B | $3.72B | $2.92B | $1.99B | $1.63B | $1.28B |
| Operating Income | -$430.24M | $716.63M | $578.58M | -$65.53M | $170.28M | $378.07M | $532.37M | $614.84M |
| Interest Expense | — | — | $32.80M | $32.80M | $89.90M | $87.60M | $62.50M | $56.70M |
| Income Before Taxes | -$627.86M | $470.35M | $297.93M | -$372.78M | -$112.84M | $275.10M | $454.30M | $529.46M |
| Provision for Income Taxes | -$272.44M | -$91.43M | -$119.91M | -$158.65M | $216.12M | $33.52M | -$73.15M | $80.16M |
| Net Income | -$356.15M | $560.12M | $414.83M | -$224.06M | -$329.67M | $238.62M | $523.37M | $447.10M |
| Basic EPS | -$5.84 | $9.06 | $6.55 | -$3.58 | -$5.52 | $4.28 | $9.22 | $7.45 |
| Diluted EPS | -$5.84 | $8.65 | $6.10 | -$3.58 | -$5.52 | $4.22 | $9.09 | $7.30 |
| Basic Shares Outstanding | 60.98M | 61.84M | 63.29M | 62.54M | 59.69M | 55.71M | 56.75M | 59.98M |
| Diluted Shares Outstanding | 60.98M | 66.01M | 72.07M | 62.54M | 59.69M | 56.52M | 57.55M | 61.22M |
Analyst Estimates
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $18.24 | $9.98 | $22.48 | 6 | ↑0 ↓2 |
| Dec 2027 | $21.91 | $19.10 | $26.71 | 8 | ↑1 ↓2 |
| Dec 2028 | $25.24 | $22.71 | $31.69 | 5 | ↑1 ↓1 |
